الفهرس 
Title pageOnly 14 pages are availabe for public view
 |  | from | 125 |  |  |
| | | from | 125 | | |
Abstract
Diabetes Type 1 is the greatest common severe chronic autoimmune sickness universal, produced by the autoimmune devastation of insulin-making beta cells in the pancreas, leading to insulin shortage and the progress of hyperglycemia. Achieving good glycemic control is a primary target in the treatment of DT1 and insulin treatment remains the basis of treatment. Storing even little quantities of remaining endogenous insulin manufacture can get better glucose metabolism, decrease the danger of hypoglycemia and diabetes related vascular problems like retinopathy, nephropathy and neuropathy. Therefore, over the past 3 decades, there was numerous immunotherapy clinical experiments aimed at repressing the autoimmune disease reply versus cells by saving remaining beta-cell mass and possibly reversing DT1.
The mechanisms leading to diabetes type 1 rely on a complex mixture of genetic and ecological factors leading to the failure of marginal tolerance. Several intrinsic Treg defects have been observed in DT1, with reduced IL-two signaling, increased T regulatory programmed cell death & reduced stabilization of FOXP-3 Treg appearance. IL-two acting is a key part in the generation and keeping of marginal fitness and role of T regulatory in mice &humans. Polymorphisms in the genes of the IL-two signaling pathway associated with DT1 therefore propose that these genetic variants might modify the risk of DT1 through effects on the number or role of Tregs. The unsuitable equilibrium of regulatory/effector T cells (Treg/Teff) is vital to the development of diabetes type 1. T Regulatory cells are essential for marginal immune tolerance & the prohibition of autoimmunity and tissue injury. T regulatory cells are intrinsically well-defined by appearance of the transcription factor Foxp-3, which enhances lineage expansion and immunosuppressive role in these cells. In various circumstances like those seen in autoimmunity. A subset of T regulatory cells reply to precise ecological signals and exhibit changed stability and tissue specific heterogeneity, with additional shapes their context-dependent suppressive roles. T regulatory cells essentially express CD twenty-five, which requires continuous IL-two signaling for homeostasis and function.
Aldesleukin (IL-2) was suggested as a decent candidate for immunotherapy to stop or retard autoimmunity found on data from earlier studies suggesting an important role for the IL-two pathway in DT1 pathogenesis. IL-two plays a key role in helping the development and role of FOXP-3 + Treg, the role of which is critical in preventing autoimmunity. T regulatory cells reply to minor amounts of IL-2 than other immune system cells, such as T effector or Nature killer cells, because they express advanced levels of CD 25. Our study aimed to progress an immunomodulatory treatment for DT1 that rises immune regulation inside physiological levels. This therapy was tested on newly diagnosed mice, many of which maintain adequate insulin production to prevent diabetes complications. Therefore, it can lead to autoimmune therapy to avoid a metabolic diagnosis of DT1.
Our strategy was to explore the effects of an ultra low amount of free cytokine IL-two and IL2-loaded chitosan nanospheres on the regulatory activity of T cells during streptozotocin induction of diabetes mellitus type 1. in 90 inbred male Balb/c mice. Foxp-3 from treg cells &TGF-β release from culture supernatant of splenocytes were assessed and correlated with serum fasting insulin and glucose level. Chitosan nanoparticles have acquired increasing attention for nanomedicine, biomedical engineering and growth of new therapeutic with enhanced bioavailability enlarged sensitivity, specificity & decreased poisonousness.
The chitosan was separated from the shrimp shell. Tripolyphosphate (TPP) was used to make chitosan nanoparticles by an ionotropic gelation technique. The size & morphology of the chitosan nanoparticle were examined by a scanning electron microscope.
Treatment of diabetic mice with intraperitoneal injection of recombinant human IL-2 either as a free ultra-low dose of 20 IU / mouse / day for five consecutive days or as an only one injection of one hundred IU / mouse improved the diabetic condition with decreased blood glucose and elevated serum insulin level compared to corresponding values in untreated DT1 through the maximum significant effect at 7,14,21 days after treatment. In comparison, day 7 of free human recombinant IL-2 treatment induced a more pronounced effect on T1D reversal than human days 14 and 21.
The transcription factor FOXP-3 evaluated showed that free human recombinant IL-two and human recombinant IL-two/CS NPs increased the mean level of FOXP-3 compared to the corresponding mean level in the non-treated T1D group.at 7 and 14 day after treatment increased significantly. However, free recombinant IL-2 induced a decrease in FOXP-3 at day 21.
For the evaluated cytokine TGFβ1, both free recombinant IL-2 and recombinant IL-2 / CS NPs significantly increased the mean TGFβ1 level compared to the corresponding mean level in the untreated T1D group on day 7,14,21 after treatment.
Both treatment showed increased FOXP-3 by 31% from base line of untreated T1D group by day 7 after treatment, showed increased TGFβ1 by 67% from base line ,showed increased insulin level by 34% from base line& showed decreased glucose level by 49% from base line by day 7 after treatment.
In the T1D/rIL-2 group, an important negative relationship was found among glucose and insulin levels at 7, 14& 21 days. whereas on day 14 there was a important positive relationship among FOXP-3 and glucose level.
In the T1D/ rIL-2/CS NPs group, an important negative relationship was found among glucose and insulin level at 7, 14 & 21 days. whereas in T1D/ rIL-2/CS NPs there was a important negative relationship among FOXP-3 & insulin level at 7 days